Inebilizumab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neuromyelitis Optica Spectrum Disorder

Conditions

Neuromyelitis Optica Spectrum Disorder

Trial Timeline

Jul 3, 2023 → Apr 13, 2027

NCT ID

NCT05549258

About Inebilizumab

Inebilizumab is a phase 2 stage product being developed by Amgen for Neuromyelitis Optica Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05549258. Target conditions include Neuromyelitis Optica Spectrum Disorder.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06987539	Phase 2	Recruiting	Apr 30, 2026	Mar 13, 2030	Generalized Myasthenia Gravis
NCT07222553	Phase 2	Recruiting	Apr 3, 2026	Jun 10, 2031	Immunoglobulin G4-related Disease
NCT06180278	Approved	Active	Apr 2, 2024	Jun 26, 2028	Neuromyelitis Optica Spectrum Disorder
NCT05549258	Phase 2	Recruiting	Jul 3, 2023	Apr 13, 2027	Neuromyelitis Optica Spectrum Disorder
NCT04540497	Phase 3	Active	Dec 4, 2020	Oct 31, 2028	IgG4 Related Disease

Competing Products

8 competing products in Neuromyelitis Optica Spectrum Disorder

See all competitors

Product	Company	Stage	Hype Score
Satralizumab 120 mg	Chugai Pharmaceutical	Approved	85
Satralizumab + Placebo + Baseline Treatment	Chugai Pharmaceutical	Phase 3	77
Satralizumab + Placebo	Chugai Pharmaceutical	Phase 3	77
satralizumab + azathioprine (AZA) + mycophenolate mofetil (MMF) + oral corticosteroids	Roche	Phase 3	77
Satralizumab	Roche	Phase 3	77
UPLIZNA	Amgen	Pre-clinical	22
Inebilizumab	Amgen	Approved	84
intravenous methylprednisolone	Brain Biotech	Pre-clinical	15

Other Products from Amgen